RXST — RxSight, Inc.

Summary of RxSight Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Sales: $32.6 million, down 19% year-over-year, primarily due to lower LDD (Light Adjustable Lens) sales.
• LDD Sales: 25 units sold, generating $3 million in revenue, a significant decline from 83 units and $11 million in Q4 2024.
• LAL Sales: 28,611 units sold, down 2% year-over-year but up 10% sequentially, contributing $28.2 million (86% of total sales).
• Gross Margin: Improved to 77.5% from 71.6% year-over-year, driven by a higher mix of LAL sales.
• Net Loss: $9.2 million or $0.22 per share; adjusted net loss of $1.3 million or $0.03 per share.
• Full Year 2025 Sales: $134.5 million, a 4% increase year-over-year, with LDD revenue down 48% but LAL sales up 12%.
• Cash Position: Ended 2025 with approximately $228 million in cash, cash equivalents, and short-term investments.

2. Strategic Updates and Business Highlights

• RxSight is focusing on improving clinical outcomes and practice expertise through enhanced training and support for LAL technology.
• The company aims to leverage its installed base of over 1,100 LDDs to drive same-store sales and patient outcomes.
• RxSight is pursuing international expansion methodically, focusing on building relationships with key opinion leaders and gathering clinical data in new markets.
• Recent clinical data published indicates high refractive accuracy for LALs, reinforcing the technology's value proposition.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $120 million and $135 million, implying a year-over-year decline of approximately 5% at the midpoint, primarily due to lower LDD sales.
• Gross Margin Guidance: Expected to be 70% to 72%, reflecting anticipated manufacturing absorption headwinds.
• Operating Expenses: Projected between $150 million and $160 million, reflecting ongoing investments in international expansion and U.S. sales efforts.
• Sales Expectations: Q1 2026 anticipated to be the lowest quarter, with expectations for sequential growth in subsequent quarters.

4. Bad News, Challenges, or Points of Concern

• Significant decline in LDD sales and revenue, raising concerns about the sustainability of growth.
• The company is facing headwinds from competitive pressures, particularly with new product launches from competitors in the premium IOL market.
• The guidance reflects a cautious outlook due to challenging comparisons from the previous year and potential impacts of seasonality.
• Increased operating expenses and net losses indicate ongoing financial pressure as the company invests in growth initiatives.

5. Notable Q&A Insights

• Management acknowledged the challenges of comparing Q1 2026 to a strong Q1 2025, indicating a cautious approach to growth expectations.
• Discussions highlighted the need for consistent performance and the importance of improving utilization rates within the existing installed base.
• Management is optimistic about the potential for recovery in the second half of 2026, contingent on improving market conditions and internal initiatives.
• The competitive landscape remains a concern, with expectations of new premium IOL product launches impacting market dynamics.

Overall, while RxSight is making strides in its strategic initiatives and maintaining a strong cash position, it faces significant challenges in sales performance and competitive pressures that could impact its growth trajectory in 2026.